Biotech is one of the hottest growing sectors on the markets right now, flush with cash and attracting a lot of big moves, like insider buying and M&As.
Of course, a lot of that has been driven by the success of the various mRNA COVID-19 vaccines. Pfizer Inc. (NYSE: PFE) reported a 27% profit margin at its last earnings report, and given the massive numbers of R&D projects in its pipeline, that growth is likely to continue even if COVID becomes endemic or fades away.
But there’s another biotech firm that’s blowing Pfizer completely out of the water, and I think every investor needs to get in on it now.
The post This Must-Buy Biotech Firm Makes Over Double Pfizer’s Profits appeared first on Money Morning – We Make Investing Profitable.